関連ニュース

FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant res

Investors seeking a more consistent performance profile from their large-cap growth allocation may benefit from an approach that goes beyond the market-cap-weighted approach offered by many passive fu

The once-weekly ​treatment could reduce the number of injections by more ⁠than 300 per year compared with once-daily basal insulin, ​Eli Lilly said.

Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the com

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs

The Amplify Weight Loss Drug & Treatment ETF (THNR) just refreshed its holdings to keep pace with where the weight-loss drug race is heading. Its underlying index, the VettaFi Weight Loss Drug & Treat

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase

Jamie Dimon compares regulations to "barnacles on a boat" in a new Treasury Department video featuring top CEOs praising President Trump's pro-growth agenda.

Crude oil prices surged above $100 as drone attacks forced Saudi Arabia to shut its critical East-West pipeline, threatening up to 4% of global supply. Repair timelines for the Saudi pipeline remain u

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharm

All too often, when investors look at the healthcare sector, they mostly see its value for its defensive merits. However, that view may be shortsighted and miss the broader picture in today's market.

I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings

Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved r

NEW YORK CITY and NEW ORLEANS, Aug. 28, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Eli Lilly and Co. (NYSE:LLY) shares are trading lower Wednesday, pulling back after the stock notched an all-time high just last week, even as the company separately reported positive real-world data

Eli Lilly has strengthened its global obesity drug market dominance, outpacing Novo Nordisk despite intensifying competition and pricing pressures. LLY's US market share has plateaued at 60–61%, but r

Argent Trust Co grew its position in shares of Eli Lilly and Company (NYSE: LLY) by 7.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and E

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating highe

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patie